Jefferies Raises PT On Pharmaceutical Product Development To $33

February 10, 2011 8:05 AM | 8 seconds read |

Jefferies & Company has raised the price target on Pharmaceutical Product Development PPDI from $32 to $33 and maintains its Buy rating.

Posted In: Price Target Analyst Ratings Health Care Jefferies & Company Life Sciences Tools & Services pharmaceutical product development

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.